Metrics Inc. Expands Staff with New Formulation Scientist
Dr. Michael DeHart develops solid-dose formulations for Phase I-III clinical trial materials.
Greenville, NC, February 15, 2013 --(PR.com)-- Metrics Inc. has added a new formulation scientist to its growing staff of pharmaceutical chemists.
Dr. Michael DeHart manages all aspects of personnel and operations related to formulating and manufacturing a client’s pharmaceutical materials for Phase I, II and III clinical trials.
In his new position, DeHart also is responsible for scale up and validation of clinical trial materials, and manufacturing and packaging clinical trial batches under Current Good Manufacturing Practices (cGMP) guidelines. He supervises technology transfers and serves as Metrics’ experimental design expert in both formulation development and process optimization areas.
Before joining Metrics, DeHart worked for several contract pharmaceutical manufacturing companies, where his responsibilities involved reverse engineering and developing analytical methods. Most recently, he was a development scientist at a commercial manufacturing site for Catalent Pharma Solutions, where he facilitated the technology transfer and scale up of solid oral dosage forms.
DeHart earned his doctorate in pharmaceutical sciences at the University of Kentucky. He holds bachelor’s degrees in biology and chemistry from Asbury College.
Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.
The company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.
Within the past five years, Metrics has conducted more than 75 FTIM studies while simultaneously producing 700-plus batches of CTM.
Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.
Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.
Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. Learn more at metricsinc dot com.
Dr. Michael DeHart manages all aspects of personnel and operations related to formulating and manufacturing a client’s pharmaceutical materials for Phase I, II and III clinical trials.
In his new position, DeHart also is responsible for scale up and validation of clinical trial materials, and manufacturing and packaging clinical trial batches under Current Good Manufacturing Practices (cGMP) guidelines. He supervises technology transfers and serves as Metrics’ experimental design expert in both formulation development and process optimization areas.
Before joining Metrics, DeHart worked for several contract pharmaceutical manufacturing companies, where his responsibilities involved reverse engineering and developing analytical methods. Most recently, he was a development scientist at a commercial manufacturing site for Catalent Pharma Solutions, where he facilitated the technology transfer and scale up of solid oral dosage forms.
DeHart earned his doctorate in pharmaceutical sciences at the University of Kentucky. He holds bachelor’s degrees in biology and chemistry from Asbury College.
Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.
The company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.
Within the past five years, Metrics has conducted more than 75 FTIM studies while simultaneously producing 700-plus batches of CTM.
Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.
Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.
Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. Learn more at metricsinc dot com.
Contact
Metrics, Inc.
Karen Stinneford
919-833-9102
http://www.metricsinc.com
Karen Stinneford
919-833-9102
http://www.metricsinc.com
Contact
Categories